Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRVB

Provention Bio (PRVB) Stock Price, News & Analysis

Provention Bio logo

About Provention Bio Stock (NASDAQ:PRVB)

Advanced Chart

Key Stats

Today's Range
$24.98
$24.98
50-Day Range
$23.74
$24.98
52-Week Range
$3.18
$25.00
Volume
218,200 shs
Average Volume
2.28 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

Macrogenics Inc MGNX
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Sanofi completes Provention Bio acquisition
See More Headlines

PRVB Stock Analysis - Frequently Asked Questions

Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.08. The business had revenue of $0.68 million for the quarter, compared to analyst estimates of $3.75 million. Provention Bio had a negative trailing twelve-month return on equity of 103.36% and a negative net margin of 880.69%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Provention Bio investors own include NVIDIA (NVDA), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Meta Platforms (META), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
11/04/2021
Today
4/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,570,000.00
Net Margins
-880.69%
Pretax Margin
-984.54%

Debt

Sales & Book Value

Annual Sales
$12.90 million
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
17.84

Miscellaneous

Free Float
82,365,000
Market Cap
$2.37 billion
Optionable
Not Optionable
Beta
2.47
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PRVB) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners